UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | July 14, 2011 |
Endocyte, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | 001-35050 | 35-1969-140 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana | | 47906 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | 765-463-7175 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On July 14, 2011, Endocyte, Inc. (the "Company") announced that it had filed a registration statement with the Securities and Exchange Commission relating to a proposed follow on offering of common stock.
A copy of the Company’s press release announcing these events is attached as Exhibit 99.1 to this report and the information in the press release is incorporated by reference into this report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release dated July 14, 2011
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | Endocyte, Inc. |
| | | | | |
| July 15, 2011 | | By: | | /s/ Michael A. Sherman
|
| | | | |
|
| | | | | Name: Michael A. Sherman |
| | | | | Title: Chief Financial Officer |
Exhibit Index
| | | |
| Exhibit No. | | Description |
| |
|
99.1 | | Press release dated July 14, 2011 |
